Published in Br J Clin Pharmacol on February 01, 1990
A computational model of altered gait patterns in parkinson's disease patients negotiating narrow doorways. Front Comput Neurosci (2014) 0.85
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. Br J Clin Pharmacol (1993) 0.81
Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med (1969) 6.16
On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology (1975) 1.96
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry (1986) 1.84
Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature (1978) 1.52
"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology (1974) 1.44
3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci (1975) 1.26
Walking patterns of men with parkinsonism. Am J Phys Med (1978) 1.18
The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor. Arch Neurol (1977) 1.16
Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease. Neurology (1974) 1.16
Gait as a total pattern of movement. Am J Phys Med (1967) 1.16
The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther (1971) 1.06
Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology (1975) 1.05
Motor function in the normal aging population: treatment with levodopa. Neurology (1985) 1.03
The measurement of pressures under the foot. Foot Ankle (1983) 0.93
Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease. Mayo Clin Proc (1972) 0.88
Bringing gait analysis out of the laboratory and into the clinic. Age Ageing (1988) 0.87
Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patients. J Neurol Sci (1980) 0.87
Plasma concentration of levodopa in patients with Parkinson's disease. Eur Neurol (1973) 0.86
Drug holiday and management of Parkinson disease. Neurology (1980) 0.85
Determination of urinary and plasma dihydroxyphenylalanine by coupled-column high-performance liquid chromatography with C8 and C18 stationary phases. J Chromatogr (1984) 0.83
Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine. J Neurol Neurosurg Psychiatry (1975) 0.83
"On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma. J Neural Transm (1984) 0.82
The L-dopa on-off effect in Parkinson disease: treatment by transient drug withdrawal and dopamine receptor resensitization. Ann Neurol (1978) 0.81
Senile gait. A distinct neurologic entity. Clin Geriatr Med (1985) 0.78
DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA. Clin Chim Acta (1973) 0.77
Can digoxin dose requirements be predicted? Br J Clin Pharmacol (1976) 2.43
Specific impedance of cerebral white matter. Exp Neurol (1965) 2.16
A quinine a day keeps the leg cramps away? Br J Clin Pharmacol (1987) 1.96
Salbutamol aerosol causes a tachycardia due to the inhaled rather than the swallowed fraction. Br J Clin Pharmacol (1980) 1.61
Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. Br Med J (1977) 1.55
Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand (1999) 1.48
Effects of nifedipine on resistance vessels, arteries and veins in man. Br J Clin Pharmacol (1980) 1.48
Digoxin prescribing: an evaluation of clinical judgment. Br Med J (1978) 1.41
Ideal sampling time for drug assays. Br J Clin Pharmacol (1980) 1.40
Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand (1999) 1.38
Bradyphrenia and parkinsonism. Age Ageing (1994) 1.38
Nifedipine in the treatment of hypertension: report of a double-blind controlled trial. Br J Clin Pharmacol (1982) 1.34
Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci (1983) 1.25
Reducing methane emissions in sheep by immunization against rumen methanogens. Vaccine (2004) 1.23
Response of forearm resistance vessels to verapamil and sodium nitroprusside in normotensive and hypertensive men: evidence for a functional abnormality of vascular smooth muscle in primary hypertension. Clin Sci (Lond) (1982) 1.21
Hepatitis A virus-associated cholecystitis. Ann Intern Med (1994) 1.20
Adrenoceptor blockade of the circulatory responses to intravenous isoproterenol. Clin Pharmacol Ther (1978) 1.08
Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol Scand (1998) 1.01
Ethylene chlorohydrin intoxication with fatality. Arch Dis Child (1970) 0.99
Comparative dilator effect of verapamil and sodium nitroprusside in forearm arterial bed and dorsal hand veins in man: functional differences between vascular smooth muscle in arterioles and veins. Cardiovasc Res (1979) 0.98
Streptokinase in acute myocardial infarction: a controlled multicentre study in the United Kingdom. Br Med J (1976) 0.96
A score for prescribing digoxin. Br Heart J (1978) 0.95
Breadth of base whilst walking: effect of ageing and parkinsonism. Age Ageing (1998) 0.95
Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy. Br J Clin Pharmacol (1990) 0.94
Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer (1993) 0.94
Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol (1992) 0.93
Evaluation of the safety of enalapril in the treatment of heart failure in the very old. Eur J Clin Pharmacol (1988) 0.93
Is this walk normal? Age Ageing (1993) 0.88
Using genetics to control cattle parasites-the Rockhampton experience. Int J Parasitol (2000) 0.87
Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol (1987) 0.87
Bringing gait analysis out of the laboratory and into the clinic. Age Ageing (1988) 0.87
Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol (1996) 0.86
Letter: Starting digoxin. Lancet (1976) 0.86
Link between Helicobacter pylori infection and idiopathic parkinsonism. Med Hypotheses (2000) 0.86
Serum concentration monitoring of cardiac glycosides. How helpful is it for adjusting dosage regimens? Clin Pharmacokinet (1991) 0.85
Digoxin: linearity between dose and serum concentration. Br J Clin Pharmacol (1976) 0.85
Quantification of the cardinal signs of parkinsonism and of associated disability in spouses of sufferers. Age Ageing (1993) 0.84
Hypothesis: age-associated changes in gait represent, in part, a tendency towards parkinsonism. Age Ageing (1992) 0.83
Parkinsonism: differential age-trend in Helicobacter pylori antibody. Aliment Pharmacol Ther (2000) 0.83
Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients. Aliment Pharmacol Ther (2013) 0.83
Intravenous injection of gentamicin and tobramycin without impairment of hearing. J Infect Dis (1976) 0.83
Reoperative surgery for bilateral multinodular goitre in the era of total thyroidectomy. Br J Surg (2012) 0.83
Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. Eur J Clin Pharmacol (1996) 0.82
The paradox of using a 7 day antibacterial course to treat urinary tract infections in the community. Br J Clin Pharmacol (1988) 0.81
Compliance with anti-tuberculous therapy: a field trial of a pill-box with a concealed electronic recording device. Eur J Clin Pharmacol (1988) 0.81
Hypothesis: the bradyphrenia of parkinsonism is a nosological entity. Acta Neurol Scand (1993) 0.81
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. Br J Clin Pharmacol (1993) 0.81
Therapeutic drug monitoring of digoxin: help or hindrance? Eur J Clin Pharmacol (1986) 0.80